Home › NDC Lookup › RxCUI directory › RxCUI 2596778

20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection — RxCUI 2596778

Name: 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection (RxCUI 2596778)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic clinical drug

RxCUI 2596778 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2596778

Official name20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection

Concept typeSemantic clinical drug (SCD)

RxNorm statusCurrent RxNorm concept

Also known asnivolumab-relatlimab-rmbw 240 MG / 80 MG per 20 ML Injection; nivolumab-relatlimab-rmbw 240 MG / 80 MG in 20 ML Injection

FDA products mapped1

Package NDCs mapped1

Reported Medicaid activity (SDUD)245 prescriptions · 8 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Nivolumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Great question. Unlike chemotherapy, which directly attacks cancer cells (and can harm healthy cells too), Opdivo works by releasing the brakes on your own immune system. It blocks...
What exactly does Opdivo do, and how is it different from regular chemotherapy?
No, Opdivo isn't a pill. It's given as an IV infusion directly into your vein at an infusion center or clinic. Each session typically takes about 30 minutes. Depending on your spec...
How will I actually receive this medication — do I take it as a pill?

📖 Read our full Nivolumab Injection guide →

🕸️ Concept Web — How 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection RxCUI 2596778 Semantic clinical drug · SCD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 5

The active substance itself — no strength, form, or brand attached yet.
- Nivolumab 1597876 IN
- Relatlimab 2596773 IN
- Nivolumab / relatlimab 2596775 MIN
- Nivolumab-rmbw 2596770 PIN
- Relatlimab-rmbw 2596772 PIN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Opdualag 2596780 BN
Dose forms 9

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Nivolumab / relatlimab Injection 2596777 SCDF
- Nivolumab-rmbw / relatlimab-rmbw Injection 2648875 SCDFP
- Nivolumab / relatlimab Injectable Product 2596776 SCDG
- Nivolumab-rmbw / relatlimab-rmbw Injectable Product 2659412 SCDGP
- Nivolumab / relatlimab Injection [Opdualag] 2596783 SBDF
- Nivolumab-rmbw / relatlimab-rmbw Injection [Opdualag] 2654690 SBDFP
- Opdualag Injectable Product 2596782 SBDG
- Injection 1649574 DF
- +1 more in this family
Clinical & branded drugs 4

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- Nivolumab-rmbw 12 MG/ML 2596771 SCDC
- Relatlimab-rmbw 4 MG/ML 2596774 SCDC
- 20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection [Opdualag] 2596784 SBD
- Nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML [Opdualag] 2596781 SBDC

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Nivolumab-rmbw 12 MG/ML SCDC · 2596771
Relatlimab-rmbw 4 MG/ML SCDC · 2596774
Nivolumab / relatlimab Injection SCDF · 2596777
Nivolumab-rmbw / relatlimab-rmbw Injection SCDFP · 2648875
Nivolumab / relatlimab Injectable Product SCDG · 2596776
Nivolumab-rmbw / relatlimab-rmbw Injectable Product SCDGP · 2659412

Brand-Name Concepts

20 ML nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML Injection [Opdualag] SBD · 2596784
Nivolumab-rmbw 12 MG/ML / relatlimab-rmbw 4 MG/ML [Opdualag] SBDC · 2596781
Nivolumab / relatlimab Injection [Opdualag] SBDF · 2596783
Nivolumab-rmbw / relatlimab-rmbw Injection [Opdualag] SBDFP · 2654690
Opdualag Injectable Product SBDG · 2596782
Opdualag BN · 2596780

📦 FDA Products & Package NDCs

1 product · 1 package NDC

1 package NDC map to RxCUI 2596778 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
00003-7125-11	1 VIAL, SINGLE-DOSE in 1 CARTON (0003-7125-11) / 20 mL in 1...	OPDUALAG	E.R. Squibb & Sons, L.L.C.	2022-03-18

Observed labelers: E.R. Squibb & Sons, L.L.C. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J9298	Inj nivol relatlimab 3mg/1mg	1	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.